Table 1.

First line immune checkpoint inhibitors.

	Pembrolizumab	Atezolizumab
Phase	Phase II (Keynote-052)	Phase II (IMvigor 210, Cohort 1)
Patients	370	119
Dosing	200 mg every 3 weeks	1200 mg every 3 weeks
ORR	28.9% (9.5% CR)	23% (9% CR)
Duration of response	39.4% responses ongoing at ⩾48 months	70% responses ongoing at 17.2 months
Median OS	11.3 months	15.9 months
Median PFS	2 months	2.7 months
Rate of grade 3/4 treatment-related AEs (%)	19	16

AE, adverse events; CR, complete response; ORR, objective response rate; OS, overall survival; PFS, progression free survival